Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.42 |
| ▸ | MMP2 | P08253 | 18/20 | 0.42 |
| ▸ | MMP8 | P22894 | 15/20 | 0.42 |
| ▸ | MMP9 | P14780 | 14/20 | 0.42 |
| ▸ | MMP3 | P08254 | 11/20 | 0.42 |
| ▸ | MMP1 | P03956 | 7/20 | 0.42 |
| ▸ | MMP14 | P50281 | 6/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908685 | 0.91 | MMP13 (0.41) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL8313534 | 0.86 | MMP13 (0.39) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL5919374 | 0.83 | MMP13 (0.48) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL5908513 | 0.82 | MMP8 (0.50) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL5908484 | 0.82 | MMP13 (0.58) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL8313537 | 0.81 | MMP13 (0.38) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL6207085 | 0.80 | MMP13 (0.43) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL5908647 | 0.80 | MMP13 (0.47) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL6227060 | 0.78 | MMP13 (0.43) | MMP13MMP2MMP8MMP9MMP3 | |
| SCHEMBL6225293 | 0.77 | MMP13 (0.56) | MMP13MMP2MMP8MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074243-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1515951-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-08-26 | — | — | US | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | MMP1, MMP3, MMP13 | MMP13 3/4885MMP2 4/4885MMP8 45/4885 |
| US-20060074243-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | MMP3, MMP13, MMP1 | MMP13 2/4885MMP2 4/4885MMP8 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.